Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS
IST:ANGEN.E

Watchlist Manager
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS Logo
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS
IST:ANGEN.E
Watchlist
Price: 10.9 TRY 2.16%
Market Cap: 2.4B TRY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ANGEN.E stock under the Base Case scenario is 17.52 TRY. Compared to the current market price of 10.9 TRY, Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS is Undervalued by 38%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ANGEN.E Relative Value
Base Case
17.52 TRY
Undervaluation 38%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.6
P/S
P/S
Price to Sales
3.6
vs History
70
vs Industry
36
Median 3Y
7.9
Median 5Y
6.1
Industry
7.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
8
Median 3Y
3.1
Median 5Y
3.1
Industry
23.6
More Details
598.4
P/OCF
P/OCF
Price to OCF
598.4
vs History
2
vs Industry
8
Median 3Y
26.4
Median 5Y
8.4
Industry
20.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-14.7
Median 5Y
-11.9
Industry
22.9
More Details
1.5
P/B
P/B
Price to Book Value
1.5
vs History
82
vs Industry
31
Median 3Y
2.2
Median 5Y
2.1
Industry
2.8
More Details
3.4
EV/S
EV/S
Enterprise Value to Sales
3.4
vs History
65
vs Industry
32
Median 3Y
7.2
Median 5Y
5.5
Industry
7.7
More Details
5.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.3
vs History
65
vs Industry
29
Median 3Y
11.1
Median 5Y
10.2
Industry
9.6
More Details
24.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
24.2
vs History
27
vs Industry
Median 3Y
19.8
Median 5Y
11
Industry
4.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-21.8
Median 5Y
1.8
Industry
4.9
More Details
562.8
EV/OCF
EV/OCF
Enterprise Value to OCF
562.8
vs History
2
vs Industry
9
Median 3Y
22.5
Median 5Y
7.6
Industry
5.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-12.7
Median 5Y
-10.5
Industry
4
More Details
1.4
EV/IC
EV/IC
Enterprise Value to IC
1.4
vs History
89
vs Industry
34
Median 3Y
3
Median 5Y
2.5
Industry
5.1
More Details

Multiples Across Competitors

ANGEN.E Competitors Multiples
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
TR
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS
IST:ANGEN.E
2.4B TRY 3.6 -9.6 24.2 -123.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 182 884.2 -162 466.2 -197 285.8 -195 034.5
US
Abbvie Inc
NYSE:ABBV
329.2B USD 5.7 79.2 15.1 22.3
US
Amgen Inc
NASDAQ:AMGN
157.3B USD 4.6 26.5 14.3 23.5
US
Gilead Sciences Inc
NASDAQ:GILD
135.8B USD 4.7 22.8 9.9 13.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.3B USD 10.7 -120.6 25.7 26.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 060.9 -525.9 -572.7 -557.4
AU
CSL Ltd
ASX:CSL
119.8B AUD 5.1 28.4 17.5 21.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.3B USD 4.2 13.2 11.8 13.2
US
Seagen Inc
F:SGT
39.3B EUR 19.9 -60.9 -65.6 -59.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.5B USD 17.3 -150.3 -673.5 -337.5
P/E Multiple
Earnings Growth PEG
TR
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS
IST:ANGEN.E
Average P/E: 34
Negative Multiple: -9.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 466.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
79.2
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.5
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.8
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -120.6 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.9 N/A N/A
AU
CSL Ltd
ASX:CSL
28.4
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -150.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
TR
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS
IST:ANGEN.E
Average EV/EBITDA: 16.9
24.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 285.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.3
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.7
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.5
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -673.5 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
TR
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS
IST:ANGEN.E
Average EV/EBIT: 20.3
Negative Multiple: -123.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 034.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.5
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.9
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.4 N/A N/A
AU
CSL Ltd
ASX:CSL
21.9
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -337.5 N/A N/A

See Also

Summary
ANGEN.E intrinsic value, competitors valuation, and company profile.
DCF Valuation
ANGEN.E stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ANGEN.E stock valuation using valuation multiples.
Wall Street Estimates
ANGEN.E price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ANGEN.E stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 268,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.